title: Cell-signaling therapy in rheumatoid arthritis.
abstract: New treatments for rheumatoid arthritis (RA) continue to emerge to meet unsatisfied needs of a significant number of patients. The development of new, oral biologic therapy is a significant step forward, although these drugs will require further evaluation in clinical settings before their true potential is appreciated. This new, oral biologic therapy has mostly focused on inhibition of intracellular signaling. These mechanisms and the available studies regarding the efficacy and safety of specific drugs which interfere with these mechanisms are the subject of this article.
authors: The Rebecca MacDonald Centre for Arthritis and Autoimmune Diseases, Mount Sinai Hospital, 60 Murrray St., Room 2-006, Box 4, Toronto, Ontario, M5T 379, Canada. edkeystone@mtsinai.on.ca
authors: Edward
authors: E
authors: Keystone
authors: Marc D
authors: MD
authors: Cohen
mesh_terms: D018501:Antirheumatic Agents / Q000627:therapeutic use*; D001172:Arthritis, Rheumatoid / Q000188:drug therapy*; D001688:Biological Products / Q000627:therapeutic use*; D006801:Humans
chemical_list: D018501:Antirheumatic Agents; D001688:Biological Products
references: Arthritis Rheum. 2012 Nov;64(11):3531-42
references: 22899318
references: Arthritis Rheum. 2011 Feb;63(2):337-45
references: 21279990
references: Front Biosci (Landmark Ed). 2011 Jan 01;16:770-82
references: 21196202
references: Expert Rev Clin Immunol. 2012 May;8(4):319-31
references: 22607178
references: J Inflamm (Lond). 2011 Aug 24;8:21
references: 21861931
references: Best Pract Res Clin Rheumatol. 2010 Aug;24(4):513-26
references: 20732649
references: Lancet. 2013 Feb 9;381(9865):451-60
references: 23294500
references: Arthritis Rheum. 2011 Feb;63(2):329-30
references: 21279987
references: J Immunol. 2011 Apr 1;186(7):4234-43
references: 21383241
references: Autoimmunity. 2010 Nov;43(7):478-92
references: 20429843
references: Arthritis Rheum. 2012 Apr;64(4):970-81
references: 22006202
references: Arthritis Rheum. 2013 Mar;65(3):559-70
references: 23348607
references: Int Immunol. 2012 May;24(5):275-81
references: 22457216
references: J Rheumatol. 2005 Sep;32(9):1650-3
references: 16142855
references: N Engl J Med. 2012 Aug 9;367(6):508-19
references: 22873531
references: Clin Immunol. 2007 Sep;124(3):244-57
references: 17537677
references: Curr Opin Rheumatol. 2010 May;22(3):330-5
references: 20164774
references: Ann Rheum Dis. 2012 Mar;71(3):440-7
references: 22121136
references: Arthritis Rheum. 2009 Feb;60(2):335-44
references: 19180516
references: N Engl J Med. 2012 Aug 9;367(6):495-507
references: 22873530
references: Arthritis Rheum. 2009 Feb;60(2):317-20
references: 19180514
references: Ann Rheum Dis. 2008 Jul;67(7):909-16
references: 17827184
references: J Rheumatol. 2012 Apr;39(4):720-7
references: 22382341
references: Arthritis Rheum. 2008 Nov;58(11):3309-18
references: 18975322
references: Expert Rev Clin Immunol. 2008 Jan;4(1):93-112
references: 20477590
references: Arthritis Rheum. 2012 Mar;64(3):617-29
references: 21952978
references: N Engl J Med. 2010 Sep 30;363(14):1303-12
references: 20879879
references: Arthritis Care Res (Hoboken). 2011 Aug;63(8):1150-8
references: 21584942
references: Reumatol Clin. 2012 Mar-Apr;8(2):78-83
references: 22104048